Phase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment in patients with advanced solid tumours

Authors
Category Primary study
JournalAnnals of Oncology
Year 2018
This article has no abstract
Epistemonikos ID: 049e8ebc8cbbde3fd821ecd5016822667a62248a
First added on: Feb 10, 2025